SCHEMBL6839924

SCHEMBL6839924

CSc1nccc(-c2nc(N)sc2Br)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MAPK14 Q16539 4/20 0.39
▸ MAPK13 O15264 1/20 0.39
▸ MAPK12 P53778 1/20 0.39
▸ MAPK11 Q15759 1/20 0.39
▸ CCNA2 P20248 2/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ CDK5 Q00535 2/20 0.39
▸ CDK5R1 Q15078 2/20 0.39
▸ CSNK1E P49674 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17005541 0.80 LMNA (0.44) LMNAKDM4EALDH1A1HPGDMAPK14
SCHEMBL6840024 0.79 KDM4E (0.46) LMNAKDM4EALDH1A1HPGDMAPK14
SCHEMBL6840123 0.78 ALDH1A1 (0.55) LMNAMEN1MAPTKMT2AKDM4E
SCHEMBL6842595 0.76 LMNA (0.44) LMNAKDM4EALDH1A1HPGDMAPK14
SCHEMBL5779376 0.75 ALDH1A1 (0.55) LMNAMEN1MAPTKMT2AKDM4E
SCHEMBL1888770 0.75 CDK4 (0.52) LMNAMEN1MAPTALOX15ALOX12
SCHEMBL6840009 0.74 MEN1 (0.41) MEN1MAPTALOX15ALOX12KMT2A
SCHEMBL5819182 0.73 TGFBR1 (0.57) LMNAMAPTKDM4EALDH1A1MAPK14
SCHEMBL31093398 0.73 LMNA (0.48) LMNAMAPTKDM4EALDH1A1HPGD
SCHEMBL6835805 0.72 LMNA (0.47) LMNAMEN1MAPTKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040181066-A1 Tyrosine kinase inhibitors FRALEY MARK E (US) 2004-09-16 — — US disclosed
WO-2003011838-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181066-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 LMNA 3751/4885MEN1 4406/4885MAPT 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback